Evaluation of naloxone for therapy of Escherichia coli shock. Species differences.
Dogs and baboons were infused intravenously (IV) with Escherichia coli and treated with the opiate antagonist, naloxone hydrochloride, and the antibiotic, gentamicin sulfate, to determine the therapeutic efficacy of naloxone. Naloxone hydrochloride (2 mg/kg) was injected IV when one fourth of the E coli had been infused and then infused at 2 mg/kg/hr (six hours for dogs and 12 hours for baboons). Four of five naloxone-treated dogs survived permanently (greater than seven days), while all dogs that were given only E coli died. Arterial BP, blood glucose levels, PCO2, and PO2 were supported at higher levels and lesions of the gastrointestinal tract were prevented in naloxone-treated dogs. A steady decline in blood glucose levels after an initial hyperglycemia was observed in naloxone-treated baboons, indications of peripheral vasoconstriction were noted, and all baboons died within 42 hours.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D004285:Dogs; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000097:blood; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005839:Gentamicins / Q000008:administration & dosage / Q000097:blood; D009270:Naloxone / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood; D010215:Papio; D012772:Shock, Septic / Q000188:drug therapy*
D005839:Gentamicins; D009270:Naloxone; D009638:Norepinephrine; D004837:Epinephrine